Alexion Pharmaceuticals

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. The Company is engaged in the discovery, development and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer and autoimmune disorders.
Company Growth (employees)
Type
Public
HQ
New Haven, US
Founded
1992
Size (employees)
3,121 (est)
Alexion Pharmaceuticals was founded in 1992 and is headquartered in New Haven, US

Alexion Pharmaceuticals Office Locations

Alexion Pharmaceuticals has offices in New Haven, Zürich, Barcelona, London and in 26 other locations
New Haven, US (HQ)
100 College St
Zürich, CH
30 Giesshübelstrasse
Show all (31)

Alexion Pharmaceuticals Financials and Metrics

Alexion Pharmaceuticals Financials

Alexion Pharmaceuticals's revenue was reported to be $870 m in Q1, 2017
USD

Revenue (Q1, 2017)

870 m

Gross profit (Q1, 2017)

801 m

Gross profit margin (Q1, 2017), %

92%

Net income (Q1, 2017)

170 m

EBIT (Q1, 2017)

212 m

Market capitalization (19-Oct-2017)

31.6 b

Cash (31-Mar-2017)

713 m
Alexion Pharmaceuticals's current market capitalization is $31.6 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

1.6 b2.2 b2.6 b3.1 b

Revenue growth, %

44%17%18%

Cost of goods sold

233.1 m258 m

Gross profit

2.4 b2.8 b
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

636.2 m666.6 m701 m753.1 m799.1 m870 m

Cost of goods sold

39.6 m51.9 m69.4 m52 m54.1 m59 m60.6 m71.1 m69 m

Gross profit

584.2 m612.6 m642.1 m692.5 m728 m801 m

Gross profit Margin, %

92%92%92%92%91%92%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

529.9 m944 m1 b966 m

Accounts Receivable

650 m

Inventories

102.6 m176.4 m289.9 m375 m

Current Assets

2.2 b2.8 b2.4 b2.6 b
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

612 m752.2 m916.8 m1.3 b1.2 b710.2 m597.6 m762 m713 m

Accounts Receivable

440.7 m436.5 m479.9 m535.8 m512.3 m586.2 m609.3 m676.8 m660 m

Inventories

144.9 m140 m174.5 m234.3 m236.5 m294 m329.8 m363.1 m396 m

Current Assets

2.3 b2.6 b2.9 b2.5 b2.5 b2.1 b2.4 b2.6 b2.7 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

252.9 m656.9 m144.4 m399 m

Depreciation and Amortization

28.7 m46.9 m166.6 m396 m

Accounts Receivable

(120 m)(28 m)(120 m)(122 m)

Inventories

126 k(67 m)(88 m)(84 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

166.5 m177.7 m91.3 m170.2 m(183.8 m)92.2 m114.9 m94.3 m170 m

Inventories

144.9 m140 m174.5 m234.3 m236.5 m294 m329.8 m363.1 m396 m

Accounts Payable

36.1 m23.2 m52.9 m47 m47 m42.9 m29 m44.8 m61 m
USDY, 2017

Revenue/Employee

278.8 k

Financial Leverage

1.5 x
Show all financial metrics

Alexion Pharmaceuticals Market Value History

Alexion Pharmaceuticals Median Salaries

Source: 33 public H-1B filings from Alexion Pharmaceuticals

Traffic Overview of Alexion Pharmaceuticals

Alexion Pharmaceuticals Online and Social Media Presence

Alexion Pharmaceuticals Company Life and Culture

You may also be interested in